A phase II trial (NCT03925974) (Xu et al. 2023) showed that patients with HER2-expressing advanced GC or GEJA receiving KN026 had an ORR of 56% and a durable remission duration of 9.7 months. Here, ERBB2 is linked to gastric cancer.